Genzyme Tolevamer Represents New Market Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch of the non-antibiotic treatment for Clostridium difficile colitis would require the biotech to build or acquire a hospital sales force.
You may also be interested in...
Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies
“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.
Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies
“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.
Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
Wirth discusses personalized medicine and Genzyme’s development pipeline, including further plans for Mozobil.